Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients

Trial Profile

Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2013 Planned end date changed from 1 Jan 2014 to 1 May 2013 as reported by ClinicalTrials.gov record.
    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Sep 2012 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top